Bexxar/BEAM Versus Rituximab/BEAM and Autologous Stem Cell Transplantation (2011 ASH Conference)



Clinical Director of the Division of Hematologic Oncology Craig Moskowitz discusses a study where 131-iodine-tositumomab (Bexxar)/carmustine, etoposide, cytarabine, melphalan (BEAM) was compared to rituximab(R)/BEAM as the conditioning regimen followed by autologous stem cell transplantation for patients with relapsed chemotherapy sensitive diffuse large B-cell lymphoma (DLBCL).

The Bexxar/BEAM and the R/BEAM regimens produced similar two-year PFS and OS for patients with chemotherapy-sensitive relapsed DLBCL.